Robinson B W
University Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.
Thorax. 1988 Jul;43(7):508-15. doi: 10.1136/thx.43.7.508.
Increased production of the serum protease plasminogen activator is associated with tissue damage. The in vitro production of plasminogen activator by alveolar macrophages obtained by bronchoalveolar lavage was studied in 22 normal subjects and 28 patients with interstitial lung disease to determine whether plasminogen activator is produced by normal alveolar macrophages and whether this is increased in patients with interstitial lung disease. Plasminogen activator activity, measured with an iodine-125 labelled fibrin release assay, was found to be dependent on time, effector cell numbers, and plasminogen concentration. Plasminogen activator production by alveolar macrophages from 14 normal non-smokers and eight normal smokers was similar and the mean value was 0.78 (SEM 0.16) urokinase (UK) units x 10(-8)/cell/hour. Alveolar macrophages from the seven patients with cryptogenic fibrosing alveolitis and six patients with histiocytosis-X produced more plasminogen activator (1.89 (0.25) and 4.54 (1.3) x 10(-8) UK units/cell/hour respectively) than macrophages from normal subjects (p less than 0.05), whereas those from 15 patients with sarcoidosis did not (1.09 (0.2) x 10(-8) UK units/cell/hour). Exposure of normal alveolar macrophages to immune complexes enhanced plasminogen activator production to 2.07 (0.27) x 10(-8) UK units/cell/hour, whereas exposure to products of activated T cells and to purified gamma interferon reduced plasminogen activator production (to 0.38 (0.11) and 0.62 (0.11) x 10(-8) UK units/cell/hour respectively). These studies show that plasminogen activator is produced by normal human alveolar macrophages and that its production is increased in patients with cryptogenic fibrosing alveolitis and histiocytosis-X.
血清蛋白酶纤溶酶原激活物产量增加与组织损伤有关。通过支气管肺泡灌洗获取肺泡巨噬细胞，研究了22名正常受试者和28名间质性肺疾病患者肺泡巨噬细胞在体外产生纤溶酶原激活物的情况，以确定正常肺泡巨噬细胞是否产生纤溶酶原激活物，以及间质性肺疾病患者其产量是否增加。用碘 - 125标记的纤维蛋白释放试验测定纤溶酶原激活物活性，发现其依赖于时间、效应细胞数量和纤溶酶原浓度。14名正常不吸烟者和8名正常吸烟者的肺泡巨噬细胞产生纤溶酶原激活物的情况相似，平均值为0.78（标准误0.16）尿激酶（UK）单位×10⁻⁸/细胞/小时。7名隐源性纤维性肺泡炎患者和6名组织细胞增多症X患者的肺泡巨噬细胞产生的纤溶酶原激活物（分别为1.89（0.25）和4.54（1.3）×10⁻⁸ UK单位/细胞/小时）比正常受试者的巨噬细胞更多（p<0.05），而15名结节病患者的肺泡巨噬细胞则不然（1.09（0.2）×10⁻⁸ UK单位/细胞/小时）。正常肺泡巨噬细胞暴露于免疫复合物时，纤溶酶原激活物产量增加至2.07（0.27）×10⁻⁸ UK单位/细胞/小时，而暴露于活化T细胞产物和纯化的γ干扰素时，纤溶酶原激活物产量降低（分别降至0.38（0.11）和0.62（0.11）×10⁻⁸ UK单位/细胞/小时）。这些研究表明，正常人肺泡巨噬细胞可产生纤溶酶原激活物，且隐源性纤维性肺泡炎和组织细胞增多症X患者其产量增加。
